White-coat hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 1, 2014, Pages 22-29

  Martin, Catherine A ^a,b,c   Mcgrath, Barry P ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

Cardiovascular risk; Glucose intolerance; Isolated clinic hypertension; White coat hypertension

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRITE; PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; GLUCOSE INTOLERANCE; HEART LEFT VENTRICLE MASS; HOME MONITORING; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; ORGAN INJURY; POPULATION; PREVALENCE; SMOKING; TARGET ORGAN; VASODILATATION; WAIST CIRCUMFERENCE; WHITE COAT HYPERTENSION;

CARDIOVASCULAR RISK; GLUCOSE INTOLERANCE; ISOLATED CLINIC HYPERTENSION; WHITE-COAT HYPERTENSION;

BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PREVALENCE; RISK; SYMPATHETIC NERVOUS SYSTEM; WHITE COAT HYPERTENSION;

EID: 84891440496     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12114     Document Type: Article

References (58)

1. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J. Clin. Hypertens. (Greenwich) 2005; 7: 102-9.
2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-87.
3. Mancia G, Bertinieri G, Grassi G et al. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983; 2: 695-8.
4. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of blood pressure in the office: Recognizing the problem and proposing the solution. Hypertension 2010; 55: 195-200.
5. Palatini P, Dorigatti F, Roman E et al. White-coat hypertension: A selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study. J. Hypertens. 1998; 16: 977-84.
6. Niiranen TJ, Jula AM, Kantola IM, Reunanen A. Prevalence and determinants of isolated clinic hypertension in the Finnish population: The Finn-HOME study. J. Hypertens. 2006; 24: 463-70.
7. Sega R, Trocino G, Lanzarotti A et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001; 104: 1385-92.
8. Cuspidi C, Parati G. Isolated clinic hypertension in a general population. J. Hypertens. 2006; 24: 437-40.
9. Helvaci MR, Sevinc A, Camci C, Yalcin A. Treatment of white coat hypertension with metformin. Int. Heart J. 2008; 49: 671-9.
10. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
11. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: A population-based study of elderly men. Circulation 2002; 106: 63-8.
12. Mancia G, Bombelli M, Facchetti R et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J. Hypertens. 2009; 27: 1672-8.
13. Hosaka M, Mimura A, Asayama K et al. Relationship of dysregulation of glucose metabolism with white-coat hypertension: The Ohasama study. Hypertens. Res. 2010; 33: 937-43.
14. Martin CA, Cameron JD, Chen SS, McGrath BP. Two hour glucose post loading: A biomarker of cardiovascular risk in isolated clinic hypertension. J. Hypertens. 2011; 29: 749-57.
15. Martin C, Cameron J, McGrath B. Mechanical and circulating biomarkers in isolated clinic hypertension. Clin. Exp. Pharmacol. Physiol. 2008; 35: 402-8.
16. Conen D, Dieterle T, Utech K, Rimner M, Martina B. C-Reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives. Hypertens. Res. 2006; 29: 411-15.
17. Erdogan D, Caliskan M, Gullu H et al. Aortic elastic properties and left ventricular diastolic function in white-coat hypertensive individuals. Blood Press. Monit. 2006; 11: 191-8.
18. Guven A, Tolun F, Caliskan M, Ciftci O, Muderrisoglu H. C-Reactive protein and nitric oxide level in patients with white coat hypertension. Blood Press. 2012; 21: 281-5.
19. Kamel N, Gursoy A, Koseoglulari O, Dincer I, Gullu S. Isolated office hypertension: Association with target organ damage and cardiovascular risk indices. J. Natl Med. Assoc. 2006; 98: 601-6.
20. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J. Hypertens. 2003; 21: 1841-6.
21. Curgunlu A, Karter Y, Uzun H et al. Hyperhomocysteinemia: An additional risk factor in white coat hypertension. Int. Heart J. 2005; 46: 245-54.
22. Pierdomenico SD, Bucci A, Lapenna D et al. Circulating homocysteine levels in sustained and white coat hypertension. J. Hum. Hypertens. 2003; 17: 165-70.
23. Curgunlu A, Uzun H, Bavunoglu I, Karter Y, Genc H, Vehid S. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J. Hum. Hypertens. 2005; 19: 629-33.
24. Karter Y, Aydin S, Curgunlu A et al. Endothelium and angiogenesis in white coat hypertension. J. Hum. Hypertens. 2004; 18: 809-14.
25. Pierdomenico SD, Cipollone F, Lapenna D, Bucci A, Cuccurullo F, Mezzetti A. Endothelial function in sustained and white coat hypertension. Am. J. Hypertens. 2002; 15: 946-52.
26. Chen LW, Huang PH, Huang SS, Chen JW, Lin SJ. Different levels of circulating endothelial microparticles among patients with normotension, hypertension or white coat hypertension. Int. J. Cardiol. 2009; 137 (Suppl. 1): S1-2 (Abstract).
27. Gomez-Cerezo J, Rios Blanco JJ, Suarez Garcia I et al. Noninvasive study of endothelial function in white coat hypertension. Hypertension 2002; 40: 304-9.
28. Ribeiro L, Gama G, Santos A, Asmar R, Martins L, Polonia J. Arterial distensibility in subjects with white-coat hypertension with and without diabetes or dyslipidaemia. Comparison with normotensives and sustained hypertensives. Blood Press. Monit. 2000; 5: 11-17.
29. Schillaci G, Pucci G, Pirro M et al. Combined effects of office and 24-h blood pressure on aortic stiffness in human hypertension. J. Hypertens. 2011; 29: 869-75.
30. Silva JA, Barbosa L, Bertoquini S, Maldonado J, Polonia J. Relationship between aortic stiffness and cardiovascular risk factors in a population of normotensives, white-coat normotensives, white-coat hypertensives, sustained hypertensives and diabetic patients. Rev. Port. Cardiol. 2004; 23: 1533-47.
31. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin. Exp. Pharmacol. Physiol. 2007; 34: 665-71.
32. Parati G, Esler M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur. Heart J. 2012; 33: 1058-66.
33. Grassi G, Seravalle G, Trevano FQ et al. Neurogenic abnormalities in masked hypertension. Hypertension 2007; 50: 537-42.
34. Pierdomenico SD, Bucci A, Costantini F, Lapenna D, Cuccurullo F, Mezzetti A. Twenty-four-hour autonomic nervous function in sustained and 'white coat' hypertension. Am. Heart J. 2000; 140: 672-7.
35. Fagard RH, Stolarz K, Kuznetsova T et al. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J. Hypertens. 2007; 25: 2280-5.
36. Madsen LB, Rasmussen JK, Moller DS, Nyvad O, Pedersen EB. Heart rate variability in white-coat hypertension. Blood Press. Monit. 2008; 13: 65-71.
37. Palatini P, Mormino P, Santonastaso M et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998; 31: 57-63.
38. Owens PE, Lyons SP, Rodriguez SA, O'Brien ET. Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? J. Hum. Hypertens. 1998; 12: 743-8.
39. Nakashima T, Yamano S, Sasaki R et al. White-coat hypertension contributes to the presence of carotid arteriosclerosis. Hypertens. Res. 2004; 27: 739-45.
40. Polonia JJ, Gama GM, Silva JA, Amaral C, Martins LR, Bertoquini SE. Sequential follow-up clinic and ambulatory blood pressure evaluation in a low risk population of white-coat hypertensive patients and in normotensives. Blood Press. Monit. 2005; 10: 57-64.
41. Mule G, Nardi E, Cottone S et al. Metabolic syndrome in subjects with white-coat hypertension: Impact on left ventricular structure and function. J. Hum. Hypertens. 2007; 21: 854-60.
42. Kotsis V, Stabouli S, Toumanidis S et al. Target organ damage in 'white coat hypertension' and 'masked hypertension'. Am. J. Hypertens. 2008; 21: 393-9.
43. Ihm SH, Youn HJ, Park CS et al. Target organ status in white-coat hypertensives: usefulness of serum procollagen type I propeptide in the respect of left ventricular diastolic dysfunction. Circ. J. 2009; 73: 100-5.
44. Grandi AM, Solbiati F, Laurita E et al. Isolated office hypertension: A 3-year follow-up study. Blood Press. 2005; 14: 298-305.
45. Ugajin T, Hozawa A, Ohkubo T et al. White-coat hypertension as a risk factor for the development of home hypertension: The Ohasama study. Arch. Intern. Med. 2005; 165: 1541-6.
46. Mancia G, Bombelli M, Facchetti R et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226-32.
47. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J. Hum. Hypertens. 2005; 19: 801-7.
48. Ohkubo T, Kikuya M, Metoki H et al. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J. Am. Coll. Cardiol. 2005; 46: 508-15.
49. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: A population based study. Am. J. Hypertens. 2006; 19: 243-50.
50. Hanninen MR, Niiranen TJ, Puukka PJ, Johansson J, Jula AM. Prognostic significance of masked and white-coat hypertension in the general population: The Finn-Home Study. J. Hypertens. 2012; 30: 705-12.
51. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J. Am. Coll. Cardiol. 2001; 38: 238-45.
52. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short- and long-term risk of cardiovascular events in white-coat hypertension. J. Hum. Hypertens. 2008; 22: 408-14.
53. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: An updated meta analysis. Am. J. Hypertens. 2011; 24: 52-8.
54. Verdecchia P, Porcellati C, Schillaci G et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
55. Verdecchia P, Angeli F, Gattobigio R et al. The clinical significance of white-coat and masked hypertension. Blood Press. Monit. 2007; 12: 387-9.
56. Strazzullo P, D'Elia L, Cairella G, Scalfi L, Schiano di Cola M. Recommending salt intake reduction to the hypertensive patient: More than just lip service. High Blood Press. Cardiovasc. Prev. 2012; 19: 59-64.
57. Martin CA, Cameron JD, McGrath BP. Baseline predictors of future hypertension in white-coat hypertension. J. Hypertens. 2012; 30 (Suppl. 1): e65 (Abstract).
58. Batkai S, Thum T. MicroRNAs in hypertension: Mechanisms and therapeutic targets. Curr. Hypertens. Rep. 2012; 14: 79-87.